Review article: The treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 7, 2013, Pages 659-671

  Joshi, D ^a   Carey, I ^a   Agarwal, K ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; CYCLOSPORIN A; DACLATASVIR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; VIRUS RNA;

ACUTE GRAFT REJECTION; ANEMIA; ANTIVIRAL THERAPY; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; GENOTYPE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874664373     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12260     Document Type: Review

References (102)

1. Williams R,. Global challenges in liver disease. Hepatology 2006; 44: 521-6. (Pubitemid 44433707)
2. World Health Organisation. Available at: http://www.who.int. Accessed September 1, 2012.
3. Kim WR,. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-4. (Pubitemid 35253461)
4. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9. (Pubitemid 37407996)
5. Adam R, McMaster P, O'Grady JG, et al,. Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno GE. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-43. (Pubitemid 37536793)
6. Gane EJ, Portmann BC, Naoumov NV, et al,. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96. (Pubitemid 34267271)
8. Everson GT, Trotter J, Forman L, et al,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62. (Pubitemid 41061075)
9. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
10. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
12. Bruno S, Shiffman ML, Roberts SK, et al,. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
13. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
14. Prati GM, Aghemo A, Rumi MG, et al,. Hyporesponsiveness to PegIFNalpha2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol 2012; 56: 341-7.
15. Charlton M, Seaberg E, Wiesner R, et al,. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30. (Pubitemid 28405436)
16. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
17. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al,. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53: 1100-8.
18. Di Bisceglie AM, Shiffman ML, Everson GT, et al,. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
19. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH,. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15. (Pubitemid 37098838)
20. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR,. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5. (Pubitemid 34467369)
21. Forns X, Garcia-Retortillo M, Serrano T, et al,. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96. (Pubitemid 37070256)
22. Carrion JA, Martinez-Bauer E, Crespo G, et al,. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
23. Everson GT, Terrault NA, Lok AS, et al,. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 2012 [Epub ahead of print].
24. Di MV, Almasio PL, Ferraro D, et al,. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-91. (Pubitemid 47336987)
25. Roffi L, Colloredo G, Pioltelli P, et al,. Pegylated interferon-Alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008; 13: 663-73.
26. Giannini EG, Basso M, Savarino V, Picciotto A,. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med 2009; 266: 537-46.
27. Venkatraman S, Bogen SL, Arasappan A, et al,. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1- dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-Azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006; 49: 6074-86. (Pubitemid 44484951)
28. Lin K, Perni RB, Kwong AD, Lin C,. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006; 50: 1813-22.
29. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
30. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
31. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
32. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
33. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
34. Hezode C, Dorival C, Zoulim F, et al,. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012; 56; No. 4(S). Abstract 51, 217A.
35. Verna EC, Terry N, Lukose T, et al,. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV infected patients awaiting liver-transplantation. Hepatology 2012; 56: No. 4(s). Abstract 52, 218A.
36. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
37. Poordad F, Lawitz E, Reddy K, et al,. A randomised trial comparing ribavirin dose reduction versus erythropoietin for anaemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol 2012; 56: S549-60. Abstract 1419.
38. Sulkowski MS, Poordad F, Manns MP, et al,. Anaemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the sprint-2 trial. Hepatology 2012 [Epub ahead of print].
39. Sheiner PA, Schwartz ME, Mor E, et al,. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-4.
40. Machicao VI, Bonatti H, Krishna M, et al,. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92. (Pubitemid 38116877)
41. Mutimer DJ, Gunson B, Chen J, et al,. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006; 81: 7-14. (Pubitemid 43122140)
42. Prieto M, Berenguer M, Rayon JM, et al,. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-6. (Pubitemid 29024010)
43. Foxton MR, Quaglia A, Muiesan P, et al,. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-9. (Pubitemid 44024965)
44. Eurich D, Boas-Knoop S, Ruehl M, et al,. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-98.
45. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.
46. Berenguer M, Prieto M, San JF, et al,. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10. (Pubitemid 34700779)
47. Feray C, Samuel D, Thiers V, et al,. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361-5.
48. Schluger LK, Sheiner PA, Thung SN, et al,. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-6. (Pubitemid 26137034)
49. Fernandez I, Meneu JC, Colina F, et al,. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-12. (Pubitemid 44911807)
50. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-8. (Pubitemid 35154038)
51. Bahra M, Neumann UP, Jacob D, et al,. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-3.
52. Picciotto FP, Tritto G, Lanza AG, et al,. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65. (Pubitemid 46185706)
53. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87. (Pubitemid 351287553)
54. Singh N, Gayowski T, Wannstedt CF, et al,. Interferon-Alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 82-6. (Pubitemid 28100436)
55. Sheiner PA, Boros P, Klion FM, et al,. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8. (Pubitemid 28405437)
56. Mazzaferro V, Tagger A, Schiavo M, et al,. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-7. (Pubitemid 32237879)
57. Sugawara Y, Makuuchi M, Matsui Y, et al,. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-11. (Pubitemid 39507969)
58. Shergill AK, Khalili M, Straley S, et al,. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-24. (Pubitemid 40095135)
59. Chalasani N, Manzarbeitia C, Ferenci P, et al,. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98. (Pubitemid 40165372)
60. Angelico M, Petrolati A, Lionetti R, et al,. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-17. (Pubitemid 46680357)
61. Jaeckel E, Cornberg M, Wedemeyer H, et al,. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
62. Castells L, Vargas V, Allende H, et al,. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-9. (Pubitemid 40805272)
63. Dumortier J, Scoazec JY, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-74. (Pubitemid 38367790)
64. Oton E, Barcena R, Moreno-Planas JM, et al,. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348-55. (Pubitemid 44359420)
65. Carrion JA, Navasa M, Garcia-Retortillo M, et al,. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-56. (Pubitemid 46695723)
66. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
67. Xirouchakis E, Triantos C, Manousou P, et al,. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-Analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
68. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99. (Pubitemid 43945798)
69. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN,. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-8. (Pubitemid 351167989)
70. Kornberg A, Kupper B, Tannapfel A, Barthel E, Thrum K, Settmacher U,. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007; 22: 2135-42. (Pubitemid 350145594)
71. Walter T, Scoazec JY, Guillaud O, et al,. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009; 15: 54-63.
72. Bzowej N, Nelson DR, Terrault NA, et al,. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.
73. Berenguer M, Aguilera V, Prieto M, et al,. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-46.
74. Eurich D, Boas-Knoop S, Bahra M, et al,. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93: 644-9.
75. Lange CM, Moradpour D, Doehring A, et al,. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-7.
76. Castells LL, Campos I, Bilbao I, et al,. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-40.
77. Firpi RJ, Soldevila-Pico C, Morelli GG, et al,. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196-203.
78. Firpi RJ, Zhu H, Morelli G, et al,. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-7.
79. Watashi K,. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr Opin Investig Drugs 2010; 11: 213-24.
80. Hirano K, Ichikawa T, Nakao K, et al,. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292-8. (Pubitemid 351425481)
81. Garg V,. van HR, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-7.
82. Coilly A, Furlan V, Roche B, et al,. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728-34.
83. Burton JR, Everson GT,. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety and tolerability. Am J Transplant 2012; 12: 188.
84. de Oliveira Pereira AP, Shin HJ, Safdar A,. Post liver transplant therapy with telaprevir for recurrent hepatitis C. Am J Transplant 2012; 12: 430.
85. Kwo P, Ghabril M, Lacerda M, et al,. Use of telaprevir plus PEG interferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C. J Hepatol 2012; 56: S86.
86. Pungpapong S, Murphy J, Henry T, et al,. P234-III Initial experience utilising telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation. Am J Transplant 2012; 12: 430.
87. Rogers CC, Stevens DR, Kim M, et al,. P239-III telaprevir can be used safely with concomitant tacrolimus in the post transplant setting. Am J Transplant 2012; 12: 431.
88. Sam T, Tichy E, Emre S, et al,. P237-III pharmokinetic effects of boceprevir co-Administration of cyclosporine exposure in liver transplant recipients. Am J Transplant 2012; 12: 430.
89. Schilsky M sTTEea,. Boceprevir, peginterferon and ribavirin (PEGIFN/RIB) as triple antiviral therapy for recurrent hepatitis C post liver transplant: an early single center experience. Am J Transplant 2012; 12: 433.
90. Sicilia M, Sandeep Mukherjee S, Fedja A, et al,. Early experience with triple drug therapy (telaprevir, pegylated interferon a 2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation. Liver Transpl 2012; 18: S99.
91. Burton J, O'Leary J, Verna E, et al,. A multicentre study of protease inhibitor-triple therapy in HCV infected liver transplant recipients: report from the CRUSH-C group. Hepatology 2012; 56: No. Abstract 211; 297A.
92. An efficacy and safety study of telaprevir in patients with genotype 1 hepatitis C infection after liver transplantation (REPLACE). Clinicaltrials.gov: NCT01571583. Accessed November 1, 2012.
93. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M,. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-9.
94. Fontana R, Bifano M, Hindes R, et al,. First ever successful use of Daclatasvir and GS-7977, an Interferon-free oral regimen, in a liver transplant recipient with severe recurrent Hepatitis C. Hepatology 2012; 56: No. Abstract 694, p524A. 2012.
95. Study to investigate GS-7977 and ribavirin for 24 weeks in subjects with recurrent chronic HCV post liver transplant. Clinicaltrials.gov: NCT01687270. Accessed December 1, 2012.
96. Giusto M, Rodriguez M, Navarro L, et al,. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl 2011; 17: 1318-27.
97. Ward SC, Schiano TD, Thung SN, Fiel MI,. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15: 1826-33.
98. Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD,. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180-6. (Pubitemid 47205751)
99. Selzner N, Guindi M, Renner EL, Berenguer M,. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-17.
100. Fiel MI, Agarwal K, Stanca C, et al,. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861-71. (Pubitemid 351895516)
101. Levitsky J, Fiel MI, Norvell JP, et al,. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-9.
102. An open-label study to explore the clinical efficacy of GS 7977 with ribavirin administered pre-transplant in preventing hepatitis C virus (HCV) recurrence post-transplant. Clinicaltrails.gov: NCT01559844. Accessed December 1, 2012.